Growpacker Inc. Welcomes Blue Moon Founder Keith Villa as a Strategic Advisor
Momentum Public Relations
Press Release: November 26, 2018
Growpacker Inc. (“Growpacker” or the “Company”), a contract manufacturer of various THC and CBD infused edibles and beverages in the United States, is pleased to welcome Keith Villa as a strategic advisor to the company.
Keith created Blue Moon Brewing Company in 1995 as an operating unit of Coors Brewing Company, which later became MillerCoors. Keith is a third generation Coloradan with a Ph.D. in brewing science from the University of Brussels, a degree held by only a handful of people in the world.
Blue Moon’s Belgian White Ale, garnished by a Valencia orange slice, grew to become the #1 selling craft beer in the United States. During this time, Keith became a well-known brewmaster in the industry, appearing in Blue Moon advertisements, hosting beer events & dinners, serving as a celebrity & judge at beer competitions, and appearing in numerous brewing articles.
In early 2018, Keith retired from MillerCoors after 32 years and co-founded CERIA, Inc. (dba CERIA Brewing Company) with his wife, Jodi Villa. Their plan was to create an extraordinary cannabis infused de-alcoholized craft beer with THC that offered a similar onset time as alcohol. Fast-forward just 10-months later, and they have done exactly that with the Colorado launch in mid-December of CERIA’s Grainwave Belgian-Style White Ale with 5mg of THC, which will be followed by two additional styles and strengths in 2019 – an American Light Lager (2.5mg THC) and an IPA (10mg THC). These products will only be available to adult consumers 21 and up.
“We are very excited to have Keith join the team as a strategic advisor”, said Stephen Boyd, Chief Executive Officer of Growpacker. “The addition of Keith is instrumental to our company, as we believe that his experience will play a key role in developing the de-alcoholized THC-infused beverage segment, which is expected to become one of the fastest growing segments in the industry.”
Growpacker Inc., through its interest in GP Holdings, LLC, has been constructing its flagship cannabis manufacturing facility in Desert Hot Springs, California. The facility is expected to house a versatile array of processing and packaging lines that can address a multitude of product categories, including beverages (carbonated or noncarbonated teas, coffees, kombuchas, waters, beers, wines, spirits, etc), edibles (cookies, brownies, gummies, hard candies, caramels, lollipops, chocolate bars, enrobed chocolates, etc), flower products (weighted quarters, eighths, pre-rolls, etc), and other one-off type products.
The facility has been built from the ground up to adhere to FDA standards in the anticipation of a federal legalization in the near future, and is located in a city where manufacturing taxes on cannabis related products are currently zero percent, giving Growpacker a substantial competitive advantage in the manufacturing space. Growpacker expects the facility to be fully constructed by the end of Q4 2018, and expects to be in full production by the start of Q1 2019.
“We are developing one of the most versatile cannabis manufacturing facilities in California, a key infrastructure component that will accelerate the entire industry,” said Stephen Boyd. “We aim to become the go-to end-to-end cannabis manufacturing arm, which will enable companies to bring new products and brands to market exponentially faster, cheaper, and easier. The addition of Keith will bring a layer of experience that’s second to none in the industry, which will directly translate into the de-alcoholized THC-infused beverage products that we manufacture.”
About Growpacker
Growpacker Inc. is a Canadian based company, which through its American interest in GP Holdings LLC, is engaged in expanding the ancillary side of the California cannabis industry. The company offers local and international brands key services, such as formulation, manufacturing, co-packing, and distribution for THC & CBD infused products.
- Published in Business, growpacker, Marijuana, Medical Marijuana, News Home
Tetra Bio-Pharma’s Dr. Chamberland Goes to Washington!
Momentum Public Relations
Press Release: November 26, 2018
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), is pleased to update the market that Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma will be travelling to Washington, D.C. today for individual meetings with six high-ranking U.S. Senators.
The meetings, scheduled for November 26th and 27th, have a mutually beneficial purpose, namely expanding Tetra’s existing work with Health Canada and the FDA in the United States as well as briefing the Senators on Tetra Bio-Pharma’s unique approach which combines the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
Tetra Bio-Pharma is the only company in North America, in addition to GW Pharmaceuticals, to work with both the FDA and Health Canada on clinical trial programs investigating cannabis and cannabinoid-based products for medical use. Tetra is currently recruiting patients for several clinical trials, including advanced cancer pain and a head to head trial investigating cannabis versus fentanyl in the treatment of breakthrough cancer pain, with the ultimate goal of reducing opioid use.
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including the ability to obtain orphan drug status, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions, the success of the products mentioned above and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
For further information, please contact Tetra Bio-Pharma Inc.
Robert (Bob) Bechard
Executive Vice President, Corporate Development and Licensing
514-817-2514
Investors@tetrabiopharma.com
- Published in Life Sciences, Medical Marijuana, News Home, Tetra Bio Pharma
MedX Health completes $182,000 closing of placement
Momentum Public Relations
Press Release: November 23, 2018
MedX Health Corp. (“MedX” or the “Company”) (TSX-V:MDX) announces that, pursuant to a non-brokered Private Placement Offering (the “Placement Offering”), it has completed an additional Closing of 1,137,500 Units on November 22, 2018, to raise $182,000 from accredited investors pursuant to a Private Placement Offering originally announced on October 11, 2018. Each Unit, priced at $0.16, comprises one fully paid common share and one share purchase warrant; each warrant entitles the holder to purchase one additional share at a price of $0.35 during the period up to three years from the closing date of the placement. The securities issued as a result of the Placement Offering will be restricted from trading for four months following each Closing.
Following this Closing, MedX has 135,053,901 common shares issued and outstanding.
The Company also announces that it is initiating a new, non-brokered, Private Placement offering of Units to raise up to $2.5 million from accredited investors. Each Unit in this proposed new placement will be priced at $0.16, and will comprise one fully paid common share and one share purchase warrant; each warrant will entitle the holder to purchase one additional share at a price of $0.35 during the period up to three years from the closing date of the placement. Closing of the proposed new Placement Offering is subject to all relevant regulatory and other consents and approvals, including acceptance by the TSX Venture Exchange.
About MedX
MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its DermSecure™ telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.
This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company’s limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company’s projections or forward-looking statements. All forward looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181123005259/en/
Contacts:
Scott Spearn, President and CEO
MedX Health Corp
905-670-4428 ext 229
Media Relations
Deborah Thompson
dthompson@medxhealth.com
416-918-9551
- Published in Life Sciences, MedX Health Corp., News Home, Technology
Element 79 closes qualifying transaction with Mondias
Momentum Public Relations
Press Release: November 23, 2018
On Nov. 14, 2018, Mondias Natural Products Inc. has closed its previously announced transaction with Element 79 Capital Inc.
The transaction consisted of a transaction that resulted in the reverse takeover of Element by the shareholders of Mondias by virtue of acquiring 100 per cent of the equity interest of Mondias. In connection with the reverse takeover, an aggregate of 41,882,760 common shares were issued at a deemed value of $4,397,689.80. Pursuant to the acquisition of Mondias, an aggregate of 6,882,760 warrants to purchase 6,882,760 common shares at an exercise price of 25 cents per share until June 20, 2020, were granted to Mondias’s existing warrantholders. The transaction constituted Element’s qualifying transaction as such term is defined in Policy 2.4 of the TSX Venture Exchange.
Prior to completion of the transaction, Element consolidated its common shares on a one-for-1.5 basis. As part of the transaction, Element changed its name from Element 79 Capital Inc. to Mondias Natural Products Inc.
As a result of the transaction, Mondias is now a wholly owned subsidiary of Element, and Element will continue the business of Mondias, which consists in the commercialization and development of evidence-based botanical products and natural health products for the health care and bioagriculture markets. For additional information concerning Mondias’s business, please refer to Element’s filing statement with respect to the transaction dated Oct. 29, 2018, which has been filed under Element’s SEDAR profile.
Concurrently to the transaction, Mondias has closed a non-brokered private placement for total gross proceeds of $1,390,725 consisting of the issuance of 13,245,000 postconsolidation common shares of Mondias. No related parties (as such term is defined in applicable laws) were part of the private placement and no subscriber became an insider of Mondias on closing of the private placement.
Prior to the transaction, Element was a capital pool company (as defined under the policies of the TSX-V) and had not commenced commercial operations other than identifying and evaluating potential business acquisitions that would qualify as its qualifying transaction and had no assets other than cash. The TSX-V granted a sponsorship waiver for this qualifying transaction.
Final acceptance of the transaction will occur upon the issuance of a final exchange bulletin by the exchange. Upon issuance of the final exchange bulletin, the company will cease to be a capital pool company and will recommence trading on the exchange as a Tier 2 issuer. Trading in the common shares of the company will begin on the exchange after the final exchange bulletin has been issued under the symbol NHP.
Management of Mondias expects that the final exchange bulletin will be issued within the next week. Pursuant to the exchange’s policies, there will be a delay of two business days between the issuance of the final exchange bulletin and resumption to trading.
Following the completion of the transaction (on a postacquisition basis), the company has a total of 63,135,805 common shares issued and outstanding, as well as: (i) common share purchase warrants exercisable to purchase up to 6,882,760 additional common shares of the company at an exercise price of 25 cents per share until June 20, 2020; and (ii) stock options exercisable to purchase up to 400,402 additional common shares at an exercise price of 22.5 cents per share.
An aggregate of 36,333,334 common shares are subject to escrow pursuant to TSX-V escrow requirements. An aggregate of 35,000,001 common shares issued to principals pursuant to the qualifying transaction will be subject to a Tier 2 value escrow agreement instead of a Tier 2 surplus escrow agreement as previously disclosed in the qualifying transaction filing statement.
As a result of the closing of the transaction, the directors and executive officers of the company are expected to be as shown in the attached table.
Andre Rancourt Chairman of the board, director Frank Palantoni Director Bertrand Venne Director Michel Timperio Director Louis Doyle Director Jean-Philippe Gravel Chief executive officer Sabino Di Paola Chief financial officer Gilles Seguin Corporate secretary
In addition to the company’s directors and officers, Robert Brouillette will also be considered to be an insider of the company by virtue of holding more than 10 per cent of the issued and outstanding securities of the company.
Further details about the transaction and the company as the resulting issuer from the closing of the transaction are available in the filing statement.
- Published in Business, Life Sciences, Mondias Natural, News Home
Tetra Bio-Pharma Seeks Solutions for Second Hand Smoke From Cannabis
Momentum Public Relations
Press Release: November 22, 2018
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), is pleased to update the market on its strategic partnership with Sirius Air Solutions Inc. (previously known as AES) to secure a source of supply for a specialized cannabis smoke air purifying system and a mask designed for law and emergency responders.
The parties are establishing a strategic alliance to develop a medical grade air purifier and mask that will address Health Canada, labour unions and public safety concerns surrounding exposure to the second-hand smoke of cannabis.
Tetra Bio-Pharma expects orders for the mask and air purifier from caregivers, medical institutions, law enforcement agencies and security services around the world.
“This technology will enable the consumers of a smokable cannabis product to take their medication in the privacy of their home or in a medical clinic while being cared for by their families, caregivers or medical personnel,” stated Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma. “We have begun working with law enforcement representatives across the country to design a specialized mask that will alleviate the effects of second-hand smoke from cannabis while performing their duties.”
About Sirius Air Solutions Inc.
Sirius Air Solutions Inc. (SAS) is an ultra-specialized air cleaner and smoke extractor manufacturer aiming to provide efficient answers for the most demanding innovative markets. Moreover, we are specialized in particle ultra filtration of air as well as in the chemical air filtration for contaminants present in gaseous form. Our approach is based on a deep understanding of airborne contaminants in order to design unique devices that consistently strive to exceed the highest standards available to date. Every day, we challenge ourselves to offer the most effective solutions to meet the most demanding situations that are proposed.
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
- Published in Life Sciences, Medical Marijuana, News Home, Tetra Bio Pharma
North Bud Farms Provides Corporate Update
Momentum Public Relations
Press Release: November 22, 2018
North Bud Farms Inc.(CSE: NBUD) (“NORTHBUD” or the “Company”) is pleased to provide shareholders with an update on our corporate activities.
Construction of our Cannabis Production Facility in Low, Quebec
NORTHBUD is pleased to update shareholders that the construction of our cannabis production facility in Low, Quebec remains on schedule as per the timeline provided from our builder NGA Construction. Erecting of the steel structure began on the 19th of November and is expected to take approximately 30 days to complete. We expect the building to be operational in Q1 2019. Please follow our social media channels for video updates of the facility construction (https://vimeo.com/302330795) and branding out reach.
Cannabis Act Application
Migration of the application to the Cannabis Licensing Tracking System (“CLTS”) has begun in collaboration with Cannabis Consulting Inc., one of the leading consultancy firms in the industry.
Update on Janey’s Inc. Acquisition
NORTHBUD and Janey’s continue to work on finalizing the acquisition agreement to include additional product segments. To date Janey’s has fulfilled multiple orders to the Ontario Cannabis Store and intends to expand its offering in the upcoming product calls.
Corporate Initiatives
NORTHBUD wishes to inform shareholders that its Board of Directors has approved management’s request to explore business opportunities in other international jurisdictions.
“This development represents an evolution in our business since going public and we feel it is important to update shareholders and potential shareholders that we will be actively pursuing international opportunities that we believe are complementary to our core business and that should create value for shareholders as we expand NORTHBUD’s global presence,” said Ryan Brown, CEO of North Bud Farms Inc.
About North Bud Farms Inc.
North Bud Farms Inc., through its wholly-owned subsidiary GrowPros MMP Inc. which was acquired in February 2018, is pursuing a license under the Access to Cannabis for Medical Purposes Regulations (ACMPR). North Bud Farms will be constructing a state-of-the-art purpose-built cannabis production facility located on 95 acres of Agricultural Land in Low, Quebec. North Bud Farms will be focused on Pharmaceutical and Food Grade cannabinoid production in preparation for the legalization of edibles and ingestible products scheduled for October 2019.
For more information visit: www.northbud.com.
Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward- looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Such risks and uncertainties include, among others, the risk factors included in North Bud Farms’ final long form prospectus dated August 21, 2018 which is available under the issuer’s SEDAR profile at www.sedar.com.
FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
North Bud Farms Inc.
Edward Miller
VP, IR & Communications
Office: (855) 628-3420 ext. 3
investors@northbud.com
- Published in Life Sciences, Marijuana, Medical Marijuana, News Home, NorthBud
DIAGNOS Announces Final Closing of Private Placement
Momentum Public Relations
Press Release: November 21, 2018
DIAGNOS Inc. (“DIAGNOS”, the “Corporation” or the “Issuer”) (TSX Venture: ADK) (OTCQB: DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence, announces the final closing of a private placement (“Private Placement”) of 20,660,000 units (each a “Unit”) issued at $0.05 per Unit for gross proceeds of $1,033,000 following receipt of required regulatory approvals. The Private Placement was announced on November 6, 2018 and on November 9, 2018.
All monies quoted in this press release shall be stated and paid in lawful money of Canada.
About DIAGNOS
DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time and has been cleared for commercialization by several regulatory authorities such as Health Canada, the U.S. Food and Drug Administration and the European Union.
Additional information is available at www.diagnos.com and www.sedar.com.
For further information, please contact:
Mr. André Larente, President | Josh Falle | ||
DIAGNOS Inc. | Momentum PR | ||
Tel: 450-678-8882 ext. 224 | Tel: 514-416-4656 | ||
alarente@diagnos.ca | josh@momentumpr.com |
- Published in Diagnos, Life Sciences, News Home, Technology
DIAGNOS Enters into a Shares for Debt Transaction
Momentum Public Relations
Press Release: November 21, 2018
DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence, announces today it has entered into a shares for debt arrangement in which the Corporation is issuing 900,000 common shares (each a “Share”), at a deemed price of $0.05 per Share, in settlement for interests payable in the amount of $45,000 on outstanding unsecured convertible notes (each a “Note”) totaling $900,000.
Satisfying this outstanding indebtedness with shares was undertaken in order to preserve the Corporation’s cash for operational purposes.
Two Note holders eligible to receive common shares as part of the shares for debt transaction are considered “related parties” of the Corporation within the meaning of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). One person related to one Note holder, as well as one other Note holder will each receive 200,000 common shares as part of the transaction. The transaction is exempt from the valuation requirement and the minority approval requirement prescribed in MI 61-101 based on the fact that the fair market value of the related parties’ participations in the shares for debt transaction does not exceed 25% of DIAGNOS’ market capitalization.
Shares issued as part of the shares for debt arrangement are subject to a statutory four-month hold period from the date of issuance ending March 21, 2019.
The issuance of shares is subject to receipt of all required approvals, including the approval of the TSX Venture Exchange, as well as the execution of formal documentation.
All monies quoted in this press release shall be stated and paid in lawful money of Canada.
About DIAGNOS
DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time and has been cleared for commercialization by several regulatory authorities such as Health Canada, the U.S. Food and Drug Administration and the European Union.
Additional information is available at www.diagnos.com and www.sedar.com.
For further information, please contact:
Mr. André Larente, President | Josh Falle |
DIAGNOS Inc. | Momentum PR |
Tel: 450-678-8882 ext. 224 | Tel: 514-416-4656 |
alarente@diagnos.ca | josh@momentumpr.com |
- Published in Diagnos, Life Sciences, News Home, Technology
Tetra Bio-Pharma Enters into Binding Proposal with Quantum Pharma Inc.
Momentum Public Relations
Press Release: November 20, 2018
Tetra Bio-Pharma Inc. (“Tetra” or “TBP”), (TSX VENTURE: TBP) (OTCQB: TBPMF), and Quantum Pharma Inc. (“Quantum”) today announced the signing of a binding proposal (the “Proposal“) for exclusive access to a Health Canada licensed facility (i.e., Drug Establishment License; DEL) that enables the company to produce cannabis and cannabinoid drug products for Tetra’s and Panag Pharma’s development activities including the ocular drug formulations. Quantum Pharma owned by Dr. Peter Ford was the GMP manufacturing division of Ford’s Family Pharmacy and Wellness Centre. Their formulation expertise will enable Tetra to develop innovative products for future clinical trials.
The Proposed Transaction is expected to provide Tetra with:
- Exclusive access to a Health Canada licensed facility (DEL) to fabricate cannabis and cannabinoid drug products for Tetra and Panag’s development activities;
- Cannabis and cannabinoid drug product formulation expertise; and
- The ability to manufacture products for all its clinical trials and commercial launches.
Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma stated, “We are very pleased to announce this important development to our shareholders. We have been working with Ford’s Family Pharmacy and Wellness Centre since 2016. Dr. Peter Ford and his team have created several innovative formulations and instruments for the fabrication of Tetra’s prescription drugs. This exclusive agreement not only secures the innovations and production know-how developed for Tetra, but also protects these assets from an acquisition by a competitor. Quantum Pharma will be an exclusive partner to Tetra and Panag enabling us to execute our future planned trials as well as prepare for our product launches.”
Dr. Chamberland further stated, “Tetra has already entered into various agreements to ensure the supply meets the demand for cannabis, THC and CBD-based products with partners including Aphria Inc., True North Cannabis, a USA-based synthetic cannabinoid manufacturer and a phytocannabinoid supplier. With the expected completion of the Panag acquisition, Tetra will become vertically integrated with drug development capabilities that range from discovery all the way through to commercial launch. Our partnerships with Genacol Corporation and Kombucha Baby Brewing Company and its partners provides Tetra with a global sales and distribution platform for the commercialization of OTC drug and wellness products. In addition, Tetra has also established distribution and sales agreements with two pharmaceutical companies for its PPP001 prescription drug product.”
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Health Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
- Published in Life Sciences, Medical Marijuana, News Home, Tetra Bio Pharma